David Dai is an accomplished professional with extensive experience in the biotech sector. Currently serving as a Director at UBS since April 2024, David previously held the position of Vice President and Senior Biotech Analyst at SMBC Nikko Securities America, Inc. from April 2021 to June 2023. David's career also includes notable roles at Barclays Investment Bank, Jefferies, and Merck, where responsibilities encompassed equity research, scientific experimentation, and investments in life sciences. David has contributed to significant deal transactions, deal evaluations, and has a strong background in oncology research, underpinned by educational qualifications including an MBA in Finance from The University of Chicago Booth School of Business, a Master's in Biotechnology from Harvard University, and a BSc in Cell Biology and Genetics from The University of British Columbia.
This person is not in the org chart
This person is not in any teams
This person is not in any offices